Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- CureApp Kicks Off Japan PIII Study for NASH Therapeutic App
February 21, 2024
- Mitsubishi Tanabe Files OD Tablet Form for Canalia in Japan
February 21, 2024
- Gilead Japan Ramping Up Sales Force with Trodelvy Now under Review
February 20, 2024
- Ono, InveniAI Pair Up for AI-Powered Drug Discovery
February 20, 2024
- Kyowa Kirin’s Phozevel Now Available for Hyperphosphatemia
February 20, 2024
- Daiichi Sankyo’s TROP2 ADC Now under US FDA Review for Lung Cancer
February 20, 2024
- Active Pharma Hid Botched API Production, Source Reveals Details of Violations
February 19, 2024
- Sawai Group President Says US Biz Exit was Due to Lack of Foresight
February 19, 2024
- Vital KSK, 3 Other Firms Invest in LinDo to Drive Japan Launch of Innovative Drugs
February 19, 2024
- Astellas, Kelonia Join Hands to Develop In Vivo Cell Therapies
February 19, 2024
- UCB Rolls Out gMG Drug Zilbrysq in Japan
February 19, 2024
- Sandoz Launches Promotion for Humira Biosimilar in Japan
February 19, 2024
- Japan Awards Priority Review for Keytruda/Padcev in Bladder Cancer: Astellas
February 19, 2024
- Otsuka’s IgA Nephropathy Drug Gets FDA Breakthrough Tag
February 19, 2024
- SC Autoinjector Pen Versions of Metoject Approved in Japan: Eisai/Medac
February 16, 2024
- Evrysdi Filed for Pre-Symptomatic SMA in Japan: Chugai
February 16, 2024
- Cancer Specialist BeiGene Set to Enter Japan Market as Early as This Year
February 16, 2024
- Ono Strikes New Oncology Pact with Numab
February 15, 2024
- Takeda Files Immunoglobulin Hyqvia in Japan
February 15, 2024
- Otsuka’s 2023 Pharma Sales Climb 20% on 4 Global Brands
February 15, 2024
ページ
Japan is ramping up its push to spread regional formularies nationwide, a policy expected to standardize treatments, strengthen supply resilience,…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…